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Background: Elucidating the histological characteristics of normal vascular smooth muscle cells (VSMCs) is
important for understanding mechanisms of development, disease etiology and the remodeling and/or
regeneration process of the vessel. However, knowledge regarding VSMCs is focused primarily on the artery.
Although the characteristics of each great vessel are documented, few studies have examined VSMCs in parallel
within each great vessel. The present study focused on comparing characteristics of canine VSMCs within the aorta
(Ao), branch pulmonary artery (bPA), main pulmonary artery (mPA) and inferior vena cava (IVC), simultaneously.
Results: Western blot and immunohistochemistry were used to determine VSMC protein content for alpha smooth
muscle actin (ASMA), calponin, myosin heavy chain (MHC) and its isozyme SM2, and non-muscle myosin heavy
chain B (SMemb). Thickness and ratio of the VSMC layer were also measured. Expression levels of ASMA, calponin
and SM2 significantly differed between vessels, except between mPA and either bPA, Ao and IVC vessels.
Expression levels of MHC were significantly different in all vessels, whilst expression of SMemb was significantly
different in the Ao compared with either bPA and mPA vessels. All vessels were significantly different with respect
to total wall and VSMC layer thickness. The ratio between VSMC layer and total wall thickness was significantly
different for each vessel, except between bPA and mPA vessels. Histological analysis of the IVC revealed that the
VSMC layer does not line evenly and continuously through the long axis or transverse sections. With respect to the
pulmonary artery, calponin was expressed to a greater extent in the mPA compared with the bPA (P < 0.01*). In
contrast, MHC and SM2 were expressed to a greater extent in the bPA compared with the mPA (P < 0.01*).
Differences in VSMC distribution indicate structural differences in the proximal and distal pulmonary artery
bifurcation.
Conclusion: Our results show that the VSMC expression pattern in each great vessel is unique and suggestive of
the developmental differences between great vessels. We believe this study provides basic data for the pathology,
etiology and regenerative capability of the vessels.
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Various antibodies specific for vascular smooth muscle
cells (VSMCs) exist, although their application in recent
investigations of normal vessels has been limited. Eluci-
dation of the histological distribution of normal VSMCs
is important for understanding mechanisms of develop-
ment, causes of hypertension, occurrence of leiomyoma,
remodeling following vascular injury and regenerative
medicine approaches.* Correspondence: smatumur@hij.twmu.ac.jp
Cardiovascular Surgery, The Heart Institute of Japan, Tokyo Women’s Medical
University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
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reproduction in any medium, provided the orVascular walls comprise an endothelial layer, composed
of a tunica intima, a layer of smooth muscle cells; tunica
media; and tunica externa, outer connective tissue layer.
However, the volume and distribution of these layers dif-
fers remarkably with regard to the role of the vessels. It is
well-documented that arteries and veins display distinct
histological differences. The arterial walls consist of a
substantial smooth muscle layer, to respond to acute
hemodynamic alteration through either constriction or
dilatation. In contrast, the venous wall has a thinner
smooth muscle layer with an undefined border, to ac-
commodate blood volume changes. The architecture ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Western blot analysis of Ao, bPA, mPA and IVC. Total
protein from Ao, bPA, mPA and IVC tissues were subjected to
western blot analysis for measurement of ASMA, calponin, MHC,
SM2 and SMemb expression. Ao; ascending aorta, bPA; branch
pulmonary artery, mPA; main pulmonary artery, IVC; inferior
vena cava.
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the smooth muscle layer is still much thinner [1].
The main smooth muscle contractile proteins are actin
and myosin. The expression level of these proteins has
been reported to vary in different smooth muscle types.
Smooth muscle actin exists in several isoforms, α, β and γ.
The β-isoform generates cytoskeletal actin, whereas α and
γ generate the contractile apparatus. Actin-binding pro-
teins, such as tropomyosin, caldesmon and calponin, play
a role in the thin filament-based regulation of smooth
muscle contractility [2].
Calponin (34-kDa protein) interacts with F-actin and
tropomyosin in a Ca2+-independent manner and with
calmodulin in a Ca2+-dependent manner. It is present in
smooth muscle at the same molar concentration as
tropomyosin [2]. The myosin molecule is a hexametric
motor-enzymic protein, consisting of two myosin heavy
chains (MHC) of approximately 200 kDa and four my-
osin light chains (MLC) of approximately 16–27 kDa.
Within smooth muscle cells, MHCs exists in two
isoforms; SM1 (204 kDa) and SM2 (200 kDa) [3-5]. Two
non-muscle MHCs, NMHC-A and NMHC-B, are also
present, but are not unique to smooth muscle cells.
SM1 and SM2 genes are expressed exclusively in
smooth muscle-containing tissues throughout develop-
ment. SM1 is constitutively expressed at all developmen-
tal stages, whereas SM2 appears only after birth [6].
NMHC-B is identical to SMemb which is expressed in
the embryonic aorta and in neointimal lesions [7,8].
During development, SMemb may be down regulated
and replaced with adult smooth muscle [9] and be re-
expressed in the proliferating SMC neointima [10].
Furthermore, information on vascular smooth muscle
cell content has mainly focused on the artery. Few re-
ports compare the differences in smooth muscle cells
between arteries and veins. It has been reported that in
canine mesenteric arteries and veins, the content of
actin, MHC, MLC and calponin are similar [11]. How-
ever, the expression pattern of MHC genes is signifi-
cantly different in the inferior vena cava compared with
the aorta and pulmonary artery of fetal and adult rab-
bits [12,13].
Understanding the basic foundations of a native vascu-
lature is necessary for elucidating the development of
pathophysiology and regenerative medicine. Recently,
there has been great interest in regenerative medicine
studies. We have previously reported long-term results
of tissue-engineering vasculature in a canine vena cava
model [14]. This vasculature was well remodeled into a
native-like vessel with no calcification, stenosis, or rup-
ture. Similar studies have been carried out in the pulmo-
nary artery [15]. Nevertheless, it is difficult to measure the
regenerate level of these remodeled vasculature studies
because of a lack of information regarding native vessels.The present study investigated canine great vessels ad-
jacent to the heart, including the aorta, pulmonary artery
and vena cava, to identify differences in expression levels
of the major contractile and thin filament-binding pro-
teins and thereby fill a deficit of vascular smooth muscle
cell research.
Results
Western blot analysis
All antibodies reacted positively to their respective ca-
nine VSMC proteins (Figure 1). Representative data for
the contractile and thin filament-binding proteins are
shown in Figure 2. The ratios of ASMA to β actin in the
Ao, bPA, mPA and IVC were 89.17 ± 8.61, 42.15 ± 3.51,
47.26 ± 5.79 and 15.08 ± 2.85, respectively. Significant
differences were observed in all vessels (p < 0.01), except
in bPA vs. mPA (p = 0.70). The ratios of calponin to
β actin in the Ao, bPA, mPA and IVC were 20.8 ± 1.14,
7.94 ±1.35, 23.2 ± 1.15 and 1.50 ± 0.18, respectively. Sig-
nificant differences were observed in all vessels (p <0.01),
except in the Ao vs. mPA (p =0.18). The ratios of MHC to
β actin in the Ao, bPA, mPA and IVC were 1.88 ± 0.17,
4.96 ± 0.70, 0.31 ± 0.05 and 0.06 ± 0.01, respectively. Sig-
nificant differences were obtained between all vessels
(p < 0.01). The ratios of SM2 to β actin in the Ao, bPA,
mPA and IVC were 2.07 ± 0.86, 1.25 ± 0.20, 0.09 ± 0.01
and 0.12 ± 0.17, respectively. There were significant differ-
ences between all vessels (p < 0.01), except in mPA vs. IVC
(p =0.24). The ratios of SMemb to β actin in the Ao, bPA,
*
*
* *
ca
lp
o
n
in
 
/ b
e
ta
 a
ct
in *
*
* *
**
SM
2 
/ b
et
a 
ac
tin
†
SM
em
b 
/ b
e
ta
 a
ct
in
*
*
*
*
*
M
H
C 
/ b
et
a
 
ac
tin **
AS
M
A 
/ b
et
a 
ac
tin
*
* *
*
Figure 2 Bar graphs showing protein densitometry of ASMA, calponin, MHC, SM2 and SMemb. All samples are normalized to β actin
protein in VSMCs of the Ao, bPA, mPA and IVC. Ao; ascending aorta, bPA; branch pulmonary artery, mPA; main pulmonary artery, IVC; inferior
vena cava. * Significant at p <0.01, † significant at p <0.05. Error bar represents standard error of the mean.
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and 0.07 ± 0.01, respectively. There were significant differ-
ences between Ao vs. bPA and Ao vs. mPA (p < 0.05).
Immunohistochemistry
Positive expression of ASMA, calponin, MHC, SM2 and
SMemb was strong and diffuse within the cytoplasm. Ex-
pression of SMemb was weakly positive (Figure 3).
In the IVC, variations in thickness of the VSMC layer
were seen after Masson’s trichrome staining. Immuno-
histochemistry of the IVC revealed variations in AMSA,
calponin, MHC and SM2 expression. IVC tissue samples
were cut transversely to evaluate variations in smooth
muscle thickness (Figure 4).
Smooth muscle thickness and ratio
The wall thickness of the Ao, bPA, mPA and IVC were
1700.8 ± 73.68 μm, 572.85 ± 30.32 μm, 1125.0 ± 48.10 μm
and 420.14 ± 25.62 μm, respectively (Figure 5, Panel A).
Significant differences were observed between all vessels.
(p <0.01) Thickness of the tunica media of the Ao, bPA,
mPA and IVC were 1368.0 ± 64.64 μm, 393.50 ± 18.50 μm,
780.79 ± 48.11 μm and 15.08 ± 1.87 μm, respectively
(Figure 5, Panel B). Significant differences were measured
between all vessels with respect to thickness of the tunica
media (p <0.01). The calculated ratio of smooth muscle/
wall thickness of the Ao, bPA, mPA and IVC were 80.22 ±
1.79%, 70.50 ± 15.1%, 68.80 ± 2.64% and 3.71 ± 0.42%, re-
spectively (Figure 5, Panel C). There were significant dif-
ferences between all vessels (p <0.05) except in bPA vs.
mPA (p =0.72) (Figure 6).Discussion
Vascular smooth muscle cells (VSMCs) play an important
role in vascular tone, repair, arteriogenesis, angiogenesis,
and in vascular pathology. A number of studies have
identified important information in relation to VSMCs
regarding mechanisms of atherosclerosis, restenosis, dif-
ferentiation and VSMC modulation during vascular de-
velopment. However, relatively little information is
available regarding the characteristics of canine VSMCs in
different vessel tissues such as coronary [16], cerebral [17],
renal [18], portal [19], and mesenteric [11] artery and/or
vein from each expert field. In this study, we simulta-
neously examined VSMC characteristics in the aorta, vena
cava and pulmonary arteries. This information is crucial,
especially for reconstruction of the vasculature during tis-
sue engineering approaches. Furthermore, regenerative
medicine is a fast growing and high impact research area,
with likely significant future developments. We previously
reported the use of tissue engineered vasculature in a ca-
nine venous reconstruction model and in human clinical
trials for the treatment of vascular disorders [14,20-22].
Another objective in vasculature regeneration is recon-
struction of native tissue. Accordingly, it is important to
compare with native vasculature to evaluate the extent of
regeneration. However, few studies on normal canine great
vessels, especially in the venous system and pulmonary ar-
teries, have been carried out. This basic study was there-
fore important to study VSMC characteristics in normal
canine great vessels and to set appropriate benchmarks for
subsequent studies on tissue-engineering vasculature in
animal models.
Figure 3 Immunohistochemical analysis of all vessels for ASMA, calponin, MHC, SM2 and SMemb expression. All vessels were strongly
positive for cytoplasmic ASMA, calponin, MHC and SM2. Expression of SMemb was low in all vessels. Bar = 200 μm.
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were used to study the characteristics of VSMCs in ca-
nine great vessels. These antibodies have been used else-
where to show differentiation and heterogeneity of
VSMCs in animal and human studies, with and with-
out disease. Western blot analysis using these protein
markers was performed in the young canine Ao, bPA,
mPA and IVC vessels to examine the characteristics of
VSMCs within these tissues.ASMA is an excellent smooth muscle cell [23] marker
because it is the first known protein expressed in SMC
differentiation during development and is required for
end-stage differentiation [24]. Calponin, a calcium regu-
latory protein, and MHC are exclusively expressed in
SMCs [2,5,6,9,25], and stretch strain has no effect on
smooth muscle expression [26]. It has been shown that
antibodies against calponin and MHC do not cross-react
with skeletal, cardiac non-muscle tissue myosin and
Figure 4 A, Masson’s trichrome staining of longitudinally sectioned IVC sample. B, Masson’s trichrome staining of transverse sectioned IVC
sample. Each box represents higher magnifications of the arrow head-indicated images. VSMCs (red) are unevenly and non-continuously aligned
in the long axis and circumference with inconsistencies between randomized sample points.
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marker since it seems highly restricted to SMCs. Other
proteins, including ASMA and calponin, are also ex-
pressed in fibroblasts [23].
Quantitative western blot analysis has been previously
carried out on canine mesenteric arteries and veins;
however no differences were observed in the content of
either actin, MHC, MLC or calponin [11]. In contrast, a
difference in expression pattern of the MHC gene was
reported in a separate study on rabbit great vessels [12].
We report here that VSMC in the Ao were significantly
different to those in the IVC with respect to ASMA,
calponin, MHC and SM2 expression. Smooth muscle
thickness, total wall thickness and ratio were also signifi-
cantly different between Ao and IVC tissues. Theseresults provide further evidence that the protein content,
size and location of SMC differs within vasculature tissues.
No significant difference was observed for the ratio of
smooth muscle/total wall thickness between the bPA
and mPA in the pulmonary arteries or in ASMA concen-
tration between the mPA and bPA. However, calponin
expression was significantly higher in mPA compared
with bPA vessels. In contrast, MHC and SM2 expression
was significantly higher in bPA compared with mPA ves-
sels. These differences in distribution of the VSMC con-
tractile and thin-filament binding proteins between mPA
and bPA vessels, suggest structural differences between
proximal and distal bifurcation of the pulmonary artery.
It has been reported that the pulmonary branches de-
velop from the sixth aortic arch, while the proximal
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Figure 5 Bar graphs showing smooth muscle thickness and ratio for each vessel. A, total wall thickness. B, smooth muscle layer thickness.
C, Ratio of smooth muscle thickness in total wall thickness. Significant differences exist between all vessels with respect to total wall thickness,
smooth muscle layer and ratio. The ratio between bPA and mPA was not significantly different. Ao; Ascending aorta, bPA; branch pulmonary
artery, mPA; main pulmonary artery, IVC; inferior vena cava. * Significant at p < 0.01, † significant at p <0.05. Error bar represents standard error of
the mean.
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http://www.biomedcentral.com/1746-6148/9/54pulmonary trunk develops from cells originating in the
secondary heart field [27]. This supports our observation
and could explain the reasons for disparity in our ana-
lysis between the mPA and bPA vessels. Namely, the
characteristic differences in VSMCs likely depend on cell
origin during prenatal development.
In terms of the IVC, we first collected the tissue
samples longitudinally, 1 to 4 cm adjacent to the right
atrium. Histological observation revealed that the VSMC
layer did not line evenly and continuously through
the IVC long axis. We therefore examined the distribu-
tion of VSMCs transversely in the IVC. The thicknessFigure 6 Continuous sectioned sample of the mPA to bPA. Total wall
mPA and bPA tissues, although the ratio of smooth muscle layer / wall thic
tissues. Bar = 500 μm.of the smooth muscle layer varied in the horizontal
sections. Interestingly, some areas did not show any
smooth muscle layer. These observations indicate that
the IVC is covered with an uneven smooth muscle
layer.
According to previous studies, other antibodies are
known to cross-react in canine VSMCs [11]. However, we
were unable to identify cross-reactivity using caldesmon,
SM1 and tropomyosin-α/β antibodies in our samples. This
may be due to differences in experimental conditions and
the overall reactivity of the antibodies, and represents a
study limitation.thickness and VSMC layer thickness were significantly different between
kness was not significantly different between mPA and bPA
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In conclusion, we have characterized VSMCs in canine
great vessels using semi-quantitative western blot analysis
and immunohistochemistry. From our results, we can de-
termine that the VSMC expression pattern in each great
vessel is regulated by size and location. We believe this
current study provides the basic data for investigating vas-
cular pathology, etiology and regenerative medicine in the
aorta, pulmonary arteries and inferior vena cava.
Methods
Sample preparations
Tissues were obtained from 18 healthy adult female bea-
gle dogs (age, 24 ± 7 months) (NARC Co., Tomisato,
Japan). Vessel samples were excised during experimental
procedures or when the dogs were sacrificed. Ascending
aorta; Ao (n = 6), branch pulmonary artery; bPA (n = 6),
main pulmonary artery; mPA (n = 6), and inferior vena
cava; IVC (n = 6), were dissected out from sacrificed ani-
mals (n = 12) or from control animals (n = 6) during ex-
perimental procedures. Tissues were stored at −20°C for
western blot analysis, or embedded in 4% paraformalde-
hyde for immunohistochemical study. The study was ap-
proved by the Animal Care and Use Committee of
Tokyo Women’s Medical University.
Western blot analysis
Samples were weighed and homogenized at a 1:20 (w/v) ra-
tio of tissue to Tissue Protein Extraction Reagent (Thermo
Fisher Scientific, Rockford, IL) to extract protein. The total
protein content was determined using the Bradford assay.
Equal amounts (15 μg) of the denatured proteins were se-
parated in 4‒ 12% polyacrylamide gels (NuPAGER NovexW
Bis-Tris [Bis (2-Hydroxyethyl) amino-Tris (Hydroxymethyl)
methane-HCl] Midi Gels; Invitrogen, Carlsbad, CA) and
transferred to polyvinylidene difluoride (PVDF) membranes
using an iBLOT dry blotting system (Invitrogen). The
following antibodies were used: ASMA (1:1000; Dako,
Glostrup, Denmark), calponin (1:4000; Sigma, St Louis,
MO, USA), MHC (1:1000; Sigma, St Louis, MO, USA),
SM2 (1:1000; Abcam, Cambridge, MA, USA), and SMemb
(1:1000; Yamasa, Tokyo, Japan). β actin (1:1000; Abcam,
Cambridge, MA, USA) was used as an internal control. A
WesternBreezeW Chemiluminescent Immunodetection Kit
(Invitrogen) and BenchPro4100™ system (Invitrogen) were
used for detection of antigen-antibody complexes immo-
bilized on the PVDF membranes, according to the manu-
facturer’s protocol. After enhancement of the membranes
by treatment with chemiluminescent reagent, images were
acquired using a cooled CCD camera (LAS-3000 Mini;
Fujifilm, Tokyo, Japan) and analyzed using image ana-
lysis software (MultiGauge; Fujifilm). A 40 kDa band
MagicMark™ XP Western Protein Standard (Invitrogen)
was used to determine protein size.Immunohistochemistry
Tissue samples were longitudinally incised and placed
on the hard cardboard followed by fixing both ends of
the samples with metal surgical clips to maintain the
original length. The samples were then fixed in 4%
paraformaldehyde/phosphate-buffered saline (pH7.0),
embedded in paraffin, and sectioned at 4–5 μm thick-
ness using a cryostat. All samples were stained with
hematoxylin-eosin (HE), Masson’s trichrome and Victoria
blue-van Gieson. The samples were then fixed in 4% para-
formaldehyde/phosphate-buffered saline (pH7.0), embed-
ded in paraffin and sectioned at 4–5 μm thickness using a
cryostat. All samples were stained with hematoxylin-eosin
(HE), Masson’s trichrome and Victoria blue-van Gieson.
Immunostaining of the paraffin sections was performed
with ASMA (1:1000; Dako), calponin (1:4000; Sigma),
MHC (1:1000; Sigma), SM2 (1:1000; abcam) and SMemb
(1:1000; Yamasa). All histological examinations and mea-
surements were performed using a microscope (Biozero
BZ-8000; Keyence, Osaka) and analysis software (BZ-
Analyzer; Keyence).
VSMC layer thicknesses and ratio
Masson’s trichrome stained Ao (n = 6), bPA (n = 6), mPA
(n = 6) and IVC (n = 6) tissue samples were measured for
total wall thickness and VSMC layer on 5–6 randomized
points for each sample. The ratio of smooth muscle/wall
thickness was calculated from the numerical values.
Statistical analysis
The statistical significance of the findings was assessed
using the Mann–Whitney U-test. All data are shown as
means ± SEM, and P values less than 0.05 were consid-
ered to indicate statistically significant differences. IBM
SPSS Statistics for Windows version 19.0 J (IBM Japan
Ltd., Tokyo, Japan) was used for statistical analyses.
Ethics
The study was approved by the Animal Care and Use
Committee of Tokyo Women’s Medical University.
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